Login / Signup

Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis.

Yuki FurukawaSaki OguroSatomi ObataTasnim HamzaEdoardo G OstinelliKiyoto Kasai
Published in: Psychiatry and clinical neurosciences (2022)
One to two milligrams of brexpiprazole as augmentation treatment may achieve an optimal balance between efficacy, tolerability, and acceptability in the acute treatment of antidepressant-refractory depression. However, the small number of included studies limit the reliability of the results. Further research is required to validate the findings.
Keyphrases
  • major depressive disorder
  • systematic review
  • depressive symptoms
  • bipolar disorder
  • case control
  • stem cells
  • sleep quality
  • intensive care unit
  • physical activity
  • meta analyses
  • acute respiratory distress syndrome